Literature DB >> 7610844

Otoneurological observation and classification of Harada's disease presenting with aural symptoms, especially vertigo.

Y Yoshimoto1.   

Abstract

Harada's disease is an uncommon autoimmune disease affecting melanocytes located in the uvea, inner ear, skin, hair, and meninges. A classification of Harada's disease presenting with aural symptoms, especially vertigo, was devised on the basis of otoneurological findings. Peripheral vestibular dysfunction, such as staggering in the stepping test, rotato-horizontal or horizontal nystagmus, and diminished labyrinthine function in the caloric nystagmus test, was observed in the vast majority of these patients. Harada's disease with such features was designated as the peripheral type, and was further divided into vestibular, cochleo-vestibular, and cochlear subtypes. Patients only rarely presented with symptoms or signs of central nervous system involvement, and Harada's disease with such features was designated as the central type.

Entities:  

Mesh:

Year:  1995        PMID: 7610844     DOI: 10.3109/00016489509121883

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  3 in total

Review 1.  Vertigo and autoimmunity.

Authors:  Roberto Bovo; Andrea Ciorba; Alessandro Martini
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-10-16       Impact factor: 2.503

2.  Spatial visualization of comprehensive brain neurotransmitter systems and neuroactive substances by selective in situ chemical derivatization mass spectrometry imaging.

Authors:  Reza Shariatgorji; Anna Nilsson; Elva Fridjonsdottir; Nicole Strittmatter; Andreas Dannhorn; Per Svenningsson; Richard J A Goodwin; Luke R Odell; Per E Andrén
Journal:  Nat Protoc       Date:  2021-06-02       Impact factor: 13.491

Review 3.  Update on Vertigo in Autoimmune Disorders, from Diagnosis to Treatment.

Authors:  Laura Girasoli; Diego Cazzador; Roberto Padoan; Ennio Nardello; Mara Felicetti; Elisabetta Zanoletti; Franco Schiavon; Roberto Bovo
Journal:  J Immunol Res       Date:  2018-09-26       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.